Prognostic factors and survival prediction in HER2‐positive breast cancer with bone metastases: A retrospective cohort study

Abstract Background Bone is the most common metastatic site of breast cancer. The developmental pattern of bone metastasis differs in different molecular subtypes. The prognostic factors of HER2‐positive breast cancer with bone metastases require further investigation. The goal of this retrospective...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xiaoshuang Lyu, Bin Luo
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	bone metastasis breast cancer HER2 nomogram prognosis SEER Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/d572839aa3e945bf9392ac4e07701d91
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d572839aa3e945bf9392ac4e07701d91
record_format	dspace
spelling	oai:doaj.org-article:d572839aa3e945bf9392ac4e07701d912021-11-22T09:08:48ZPrognostic factors and survival prediction in HER2‐positive breast cancer with bone metastases: A retrospective cohort study2045-763410.1002/cam4.4326https://doaj.org/article/d572839aa3e945bf9392ac4e07701d912021-11-01T00:00:00Zhttps://doi.org/10.1002/cam4.4326https://doaj.org/toc/2045-7634Abstract Background Bone is the most common metastatic site of breast cancer. The developmental pattern of bone metastasis differs in different molecular subtypes. The prognostic factors of HER2‐positive breast cancer with bone metastases require further investigation. The goal of this retrospective study was to identify the clinical features and prognostic factors for HER2‐positive patients with bone metastases. Methods A total of 34,084 HER2‐positive breast cancer cases and 1204 cases of bone metastases from the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015 were analyzed to identify clinical characteristics and prognostic factors. A nomogram was constructed based on the Cox proportional hazards regression model. The C‐index, calibration curve, and receiver operating characteristic (ROC) were utilized for model validation. Results In the HER2‐positive breast cancer total population (34,084 cases), 6.2% developed metastatic diseases. Bone metastases accounted for 3.5% of the entire cohort and 56.7% of all metastatic cases. Univariate and multivariate Cox regression analyses identified seven prognostic factors for predicting cancer‐specific survival (CSS) for HER2‐positive breast cancer patients with bone metastases, including age, brain metastases, liver metastases, lung metastases, PR status, surgery, and chemotherapy. The C‐index of the nomogram was 0.74 vs. 0.78 (for 3‐year CSS) and 0.77 vs. 0.81 (for 5‐year CSS) in the model and validation cohorts, respectively. The AUCs were 0.74 vs. 0.78 (for 3‐year CSS) and 0.77 vs. 0.81 (for 5‐year CSS) in the model and validation cohorts, respectively. The calibration curves indicated favorable agreement between the actual observations and the predictions. Conclusion Our study provided population‐based clinical features and prognostic factors for HER2‐positive breast cancer patients with bone metastases and we constructed a prognostic nomogram with reliable accuracy.Xiaoshuang LyuBin LuoWileyarticlebone metastasisbreast cancerHER2nomogramprognosisSEERNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancer Medicine, Vol 10, Iss 22, Pp 8114-8126 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	bone metastasis breast cancer HER2 nomogram prognosis SEER Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	bone metastasis breast cancer HER2 nomogram prognosis SEER Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Xiaoshuang Lyu Bin Luo Prognostic factors and survival prediction in HER2‐positive breast cancer with bone metastases: A retrospective cohort study
description	Abstract Background Bone is the most common metastatic site of breast cancer. The developmental pattern of bone metastasis differs in different molecular subtypes. The prognostic factors of HER2‐positive breast cancer with bone metastases require further investigation. The goal of this retrospective study was to identify the clinical features and prognostic factors for HER2‐positive patients with bone metastases. Methods A total of 34,084 HER2‐positive breast cancer cases and 1204 cases of bone metastases from the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015 were analyzed to identify clinical characteristics and prognostic factors. A nomogram was constructed based on the Cox proportional hazards regression model. The C‐index, calibration curve, and receiver operating characteristic (ROC) were utilized for model validation. Results In the HER2‐positive breast cancer total population (34,084 cases), 6.2% developed metastatic diseases. Bone metastases accounted for 3.5% of the entire cohort and 56.7% of all metastatic cases. Univariate and multivariate Cox regression analyses identified seven prognostic factors for predicting cancer‐specific survival (CSS) for HER2‐positive breast cancer patients with bone metastases, including age, brain metastases, liver metastases, lung metastases, PR status, surgery, and chemotherapy. The C‐index of the nomogram was 0.74 vs. 0.78 (for 3‐year CSS) and 0.77 vs. 0.81 (for 5‐year CSS) in the model and validation cohorts, respectively. The AUCs were 0.74 vs. 0.78 (for 3‐year CSS) and 0.77 vs. 0.81 (for 5‐year CSS) in the model and validation cohorts, respectively. The calibration curves indicated favorable agreement between the actual observations and the predictions. Conclusion Our study provided population‐based clinical features and prognostic factors for HER2‐positive breast cancer patients with bone metastases and we constructed a prognostic nomogram with reliable accuracy.
format	article
author	Xiaoshuang Lyu Bin Luo
author_facet	Xiaoshuang Lyu Bin Luo
author_sort	Xiaoshuang Lyu
title	Prognostic factors and survival prediction in HER2‐positive breast cancer with bone metastases: A retrospective cohort study
title_short	Prognostic factors and survival prediction in HER2‐positive breast cancer with bone metastases: A retrospective cohort study
title_full	Prognostic factors and survival prediction in HER2‐positive breast cancer with bone metastases: A retrospective cohort study
title_fullStr	Prognostic factors and survival prediction in HER2‐positive breast cancer with bone metastases: A retrospective cohort study
title_full_unstemmed	Prognostic factors and survival prediction in HER2‐positive breast cancer with bone metastases: A retrospective cohort study
title_sort	prognostic factors and survival prediction in her2‐positive breast cancer with bone metastases: a retrospective cohort study
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/d572839aa3e945bf9392ac4e07701d91
work_keys_str_mv	AT xiaoshuanglyu prognosticfactorsandsurvivalpredictioninher2positivebreastcancerwithbonemetastasesaretrospectivecohortstudy AT binluo prognosticfactorsandsurvivalpredictioninher2positivebreastcancerwithbonemetastasesaretrospectivecohortstudy
_version_	1718417824321372160

Prognostic factors and survival prediction in HER2‐positive breast cancer with bone metastases: A retrospective cohort study

Ejemplares similares